Forest’s Combunox Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's combination pain therapy Combunox was approved by FDA, the company said Nov. 26
You may also be interested in...
Combunox's Future At Forest May Depend On Success Of New Trial Program
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested
Combunox's Future At Forest May Depend On Success Of New Trial Program
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested
Forest Bites At Stroke Clot Dissolver; Desmoteplase Could Have Nine-Hour Treatment Window
The company licenses U.S. and Canadian rights to Phase II plasminogen activator, derived from vampire bat saliva, from German firm PAION GmbH; desmoteplase is Forest’s first biologic product. The companies expect to initiate the rolling BLA submission as early as 2007.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: